secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K/A
Filed at:   2026-06-23T20:42:16+00:00
Accession:  0001193125-26-279630
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas
--------------------------------------------------------------------------------

- Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.
- Lilly's subsidiary is stalking horse bidder for capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger prion assets.
- Astellas acquires assets under separate agreement; terms not disclosed in this filing.
- Sangamo common stock delisted from Nasdaq on May 5, 2026; now trading on OTCQB.
- Sale subject to Bankruptcy Court approval and potential higher bids in auction process.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/0001193125-26-279630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/d68888d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer